Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.

NoNO, Inc. operates as a biotherapeutics company. It engages in the research, development, and commercialization of pharmaceuticals for the treatment of common health disorders that include strokes, traumatic brain injuries, and pains. The company was founded by Michael Tymianski and Michael W. Salter in 2003 and is headquartered in Toronto, Canada.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Brainscope is a medical neurotechnology company that improves brain health. It develops a new generation of hand-held, simple-to-use, non-invasive instruments to aid medical professionals in rapidly, accurately, and objectively assessing brain function at the initial point of care. BrainScope devices in development are based on a revolutionary and proprietary technology platform, which integrates databases of brainwave recordings with advanced developments in Digital Signal Processing (DSP), sophisticated linear and non-linear algorithms, miniaturized hardware, and disposable headset sensors. It also provides objective, diagnostic insights that enable better patient care. The company’s innovative BrainScope One system is the first and only portable, EEG-based, radiation-free platform that empowers physicians to quickly make accurate head injury assessments. It was founded in 2010 and is headquartered in Bethesda, Maryland.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease. In 2016 the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials.

Emtora Biosciences is a life science company that commercializes a new formulation of an immunosuppressant as a prostate cancer drug. The company developing a novel formulation of rapamycin, eRapa for use in preventing the onset and recurrence of cancer. It manufactures a drug to slow the aging process and its efficacy in treating age-related diseases. The eRapa is the only pharmaceutical agent to demonstrate significantly increased healthspan and lifespan in rodent models, and Science, Nature, and Time magazines proclaimed the discovery of a special formulation of rapamycin to extend one’s life and health span among the most significant and exciting scientific breakthroughs of 2009.

Cambridge University Technical Services Ltd., part of University of Cambridge, is a British company located in Cambridge. The firm provides consulting services. It was founded in 2006.

SAM Technology, Inc. is a private company headquartered in San Francisco, CA. The firm engages in research and development of biological products.

Naturex, Inc. engages in the manufacture, marketing and distribution of natural ingredients for the food, pharmaceutical and cosmetic industries. The company is headquartered in South Hackensack, NJ.

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, trading symbol NWRN.

saniva diagnostics was founded as a spin-off from Jena University Hospital, is the patent holder and is developing a motorized screening instrument for the early detection of neurodegenerative diseases.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Develops and commercializes specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions

BRAINBox Solutions, Inc. develops and manufactures tools for diagnosing mild traumatic brain injuries. It specializes in concussion, neurological biomarkers, point of care, neurocognitive testing, and diagnosis. The company was founded in 2018 and is headquartered in Richmond, VA.

USAMRMC

HitCheck is the mobile app that helps users screen for signs of a concussion in minutes — anytime, anywhere — right from their smartphone. Designed for everyday use by parents, coaches, athletic trainers, medical proffesionals and active people of all ages, the app’s game-like tests help measure brain functions and deliver real-time results so users can make smarter return-to-play decisions and share timely personalized assessments with medical practitioners to assist to monitor recovery, track concussion history, and manage team/league records from your smartphone. HitCheck offers a SaaS subscription model that allows teams and organizations to access dashboard features to manage groups of individuals with an average cost of $1.50 per person annually.